<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of central adrenal insufficiency in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of central adrenal insufficiency in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Causes of central adrenal insufficiency in children</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Condition</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Transient central adrenal insufficiency (due to pituitary or hypothalamic suppression)*</td> </tr> <tr> <td class="indent1">Cessation of chronic high-dose glucocorticoid therapy</td> <td>Most common cause of central adrenal insufficiency. These drugs reversibly suppress the hypothalamic-pituitary-adrenal axis.</td> </tr> <tr> <td class="indent1">After cure of Cushing syndrome <ul class="decimal_heading"> <li>Resection of an adrenal cortisol-secreting tumor</li> <li>Resection of an ACTH-secreting tumor</li> </ul> </td> <td>Elevated concentrations of cortisol suppress hypothalamic production of CRH, which, in turn, inhibits ACTH production from corticotroph cells.</td> </tr> <tr> <td class="indent1" colspan="2">Medications<sup>¶</sup></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Megestrol acetate (Megace) therapy</li> </ul> </td> <td>A high-dose progestin with glucocorticoid <span class="nowrap_whitespace">activity<sup>[1]</sup>.</span> Adrenal insufficiency may occur during therapy or upon withdrawal.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Chronic opioid use</li> </ul> </td> <td>Related to cumulative opioid <span class="nowrap_whitespace">dose<sup>[2]</sup>.</span></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Mifepristone</li> </ul> </td> <td>Anti-progestational agent and glucocorticoid receptor antagonist.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Antipsychotics (eg, chlorpromazine); antidepressants (imipramine)</li> </ul> </td> <td>Inhibit glucocorticoid-induced gene transcription.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Etomidate</li> </ul> </td> <td>Possible central <span class="nowrap_whitespace">effect<sup>[3]</sup>.</span></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Immune checkpoint inhibitors (<a href="https://omim.org/entry/123890" target="_blank"><em>CTLA4</em></a> blockade)</li> </ul> </td> <td>Hypophysitis; <span class="nowrap_whitespace">hypopituitarism<sup>[4]</sup>.</span></td> </tr> <tr> <td class="indent1">Anorexia nervosa</td> <td>Adrenal insufficiency is rare, although some hypothalamic dysfunction is common.</td> </tr> <tr> <td class="indent1">Critical illness-related corticosteroid insufficiency (CIRCI)</td> <td>CIRCI has characteristics of central adrenal insufficiency, with complex dysregulation of the HPA <span class="nowrap_whitespace">axis<sup>[5]</sup>.</span> CIRCI also involves primary adrenal dysfunction and tissue corticosteroid resistance.</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Permanent central adrenal insufficiency (due to pituitary and/or hypothalamic dysfunction)</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Congenital</td> </tr> <tr> <td class="indent2">Brain malformations<sup>Δ</sup> <ul class="decimal_heading"> <li>Optic nerve hypoplasia/septo-optic dysplasia (eg, <a href="https://www.omim.org/entry/601802" target="_blank"><em>HESX1</em></a>, other mutations)</li> <li>Other brain malformations, especially with midline and/or craniofacial defects</li> </ul> </td> <td>Optic nerve hypoplasia is associated with a variety of CNS and endocrine abnormalities, some with syndromic features.</td> </tr> <tr> <td class="indent2">Syndromes with hypothalamic dysfunction <ul class="decimal_heading"> <li>Prader-Willi syndrome</li> <li>ROHHAD syndrome</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent2">Genetic causes of pituitary hormone deficiencies <ul class="decimal_heading"> <li>Nonsyndromic with CPHD: <ul> <li><a href="https://www.omim.org/entry/601538" target="_blank"><em>PROP1</em></a> (CPHD2, <a href="https://www.omim.org/entry/262600" target="_blank">MIM #262600</a>)</li> <li><a href="https://www.omim.org/entry/173110" target="_blank"><em>POU1F1</em></a> (CPDH1, <a href="https://www.omim.org/entry/613038" target="_blank">MIM #613038</a>)</li> </ul> </li> <li>Syndromic with CPHD: <ul> <li><a href="https://www.omim.org/entry/164012" target="_blank"><em>NFKB2</em></a> – Immune deficiency (<a href="https://www.omim.org/entry/615577" target="_blank">MIM #615577</a>)</li> <li><a href="https://www.omim.org/entry/601802" target="_blank"><em>HESX1</em></a> – Optic nerve hypoplasia/septo-optic dysplasia (CPHD5, <a href="https://www.omim.org/entry/182230" target="_blank">MIM #182230</a>)</li> <li><a href="https://omim.org/entry/313430" target="_blank"><em>SOX3</em></a>; <a href="https://omim.org/entry/607108" target="_blank"><em>PAX6</em></a>; <a href="https://omim.org/entry/600577" target="_blank"><em>LHX3</em></a> (CPHD3); <a href="https://omim.org/entry/602146" target="_blank"><em>LHX4</em></a> (CPHD4); <a href="https://omim.org/entry/600037" target="_blank"><em>OTX2</em></a> (CPHD6)</li> </ul> </li> <li>Syndromic with isolated ACTH <span class="nowrap_whitespace">deficiency<sup>[6]</sup>:</span> <ul> <li><a href="https://www.omim.org/entry/176830" target="_blank"><em>POMC</em></a> – Obesity, red hair (<a href="https://www.omim.org/entry/609734" target="_blank">MIM #609734</a>)</li> <li><a href="https://www.omim.org/entry/604614" target="_blank"><em>TBX19</em></a> (<em>TPIT</em>) – Hypoglycemia, cholestasis (<a href="https://www.omim.org/entry/201400" target="_blank">MIM #201400</a>)</li> <li><a href="https://www.omim.org/entry/162150" target="_blank"><em>PCSK1</em></a> – Obesity, hypogonadism, hypoglycemia, chronic diarrhea (<a href="https://www.omim.org/entry/600955" target="_blank">MIM #600955</a>)</li> </ul> </li> </ul> </td> <td>Variable phenotypes, with single or multiple pituitary hormone deficiencies including ACTH deficiency, with variable order of onset and variable <span class="nowrap_whitespace">severity<sup>[6,7]</sup>.</span></td> </tr> <tr> <td class="subtitle3_left" colspan="2">Acquired</td> </tr> <tr> <td class="indent2">Brain lesion or injury<sup>Δ</sup> <ul class="decimal_heading"> <li>Brain tumor</li> <li>Brain hemorrhage</li> <li>Brain trauma or surgery</li> <li>Cranial irradiation</li> </ul> </td> <td rowspan="2">Multiple pituitary hormones may be affected (GH, LH, FSH, TSH, ACTH, and/or ADH). The most common deficits are GH, LH, and FSH, causing growth abnormalities and delayed puberty, respectively. However, these disorders also may be rarely associated with precocious puberty, the mechanism of which is unknown.</td> </tr> <tr> <td class="indent2">Infiltrative diseases<sup>Δ</sup> <ul class="decimal_heading"> <li>Iron overload (hemochromatosis, thalassemia)</li> <li>Sarcoidosis</li> <li>Langerhans cell histiocytosis</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ACTH: adrenocorticotropic hormone; CRH: corticotropin-releasing hormone; CIRCI: critical illness-related corticosteroid insufficiency; HPA: hypothalamic-pituitary-adrenal; CNS: central nervous system; ROHHAD: rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation; CPHD: combined pituitary hormone deficiency; GH: growth hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; TSH: thyroid-stimulating hormone; ADH: antidiuretic hormone (vasopressin).</p>
<p>* These disorders cause temporary isolated ACTH deficiency due to suppression of hypothalamic CRH secretion.</p>
<p>¶ Refer to UpToDate content on causes of secondary and tertiary adrenal insufficiency in adults.</p>
Δ These brain disorders may cause adrenal insufficiency by interfering with pituitary ACTH secretion (secondary adrenal insufficiency) or with hypothalamic CRH secretion (tertiary adrenal insufficiency).</div><div class="graphic_reference">References:
<ol>
<li>Li T, Cunningham JL, Gilliam WP, et al. Prevalence of Opioid-Induced Adrenal Insufficiency in Patients Taking Chronic Opioids. J Clin Endocrinol Metab 2020; 105:e3766.</li>
<li>Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.</li>
<li>Molenaar N, Bijkerk RM, Beishuizen A, et al. Steroidogenesis in the adrenal dysfunction of critical illness: impact of etomidate. Crit Care 2012; 16:R121.</li>
<li>Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 2021; 17:389.</li>
<li>Annane D, Pastores SM, Arlt W, et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med 2017; 43:1781.</li>
<li>Patti G, Guzzeti C, Di Iorgi N, et al. Central adrenal insufficiency in children and adolescents. Best Pract Res Clin Endocrinol Metab 2018; 32:425.</li>
<li>Bosch I Ara L, Katugampola H, Dattani MT. Congenital Hypopituitarism During the Neonatal Period: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome. Front Pediatr 2020; 8:600962.</li>
</ol></div><div id="graphicVersion">Graphic 56675 Version 23.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
